Cargando…

Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis

BACKGROUND: Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Márton, Kiss, Nikolett, Baka, Máté, Trásy, Domonkos, Zubek, László, Fehérvári, Péter, Harnos, Andrea, Turan, Caner, Hegyi, Péter, Molnár, Zsolt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576288/
https://www.ncbi.nlm.nih.gov/pubmed/37833778
http://dx.doi.org/10.1186/s13054-023-04677-2
_version_ 1785121088263421952
author Papp, Márton
Kiss, Nikolett
Baka, Máté
Trásy, Domonkos
Zubek, László
Fehérvári, Péter
Harnos, Andrea
Turan, Caner
Hegyi, Péter
Molnár, Zsolt
author_facet Papp, Márton
Kiss, Nikolett
Baka, Máté
Trásy, Domonkos
Zubek, László
Fehérvári, Péter
Harnos, Andrea
Turan, Caner
Hegyi, Péter
Molnár, Zsolt
author_sort Papp, Márton
collection PubMed
description BACKGROUND: Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guided AB therapy with standard of care (SOC) in critically ill patients. METHODS: We searched databases CENTRAL, Embase and Medline. We included randomized controlled trials (RCTs) comparing PCT-guided AB therapy (PCT group) with SOC reporting on length of AB therapy, mortality, recurrent and secondary infection, ICU length of stay (LOS), hospital LOS or healthcare costs. Due to recent changes in sepsis definitions, subgroup analyses were performed in studies applying the Sepsis-3 definition. In the statistical analysis, a random-effects model was used to pool effect sizes. RESULTS: We included 26 RCTs (n = 9048 patients) in the quantitative analysis. In comparison with SOC, length of AB therapy was significantly shorter in the PCT group (MD − 1.79 days, 95% CI: -2.65, − 0.92) and was associated with a significantly lower 28-day mortality (OR 0.84, 95% CI: 0.74, 0.95). In Sepsis-3 patients, mortality benefit was more pronounced (OR 0.46 95% CI: 0.27, 0.79). Odds of recurrent infection were significantly higher in the PCT group (OR 1.36, 95% CI: 1.10, 1.68), but there was no significant difference in the odds of secondary infection (OR 0.81, 95% CI: 0.54, 1.21), ICU and hospital length of stay (MD − 0.67 days 95% CI: − 1.76, 0.41 and MD − 1.23 days, 95% CI: − 3.13, 0.67, respectively). CONCLUSIONS: PCT-guided AB therapy may be associated with reduced AB use, lower 28-day mortality but higher infection recurrence, with similar ICU and hospital length of stay. Our results render the need for better designed studies investigating the role of PCT-guided AB stewardship in critically ill patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04677-2.
format Online
Article
Text
id pubmed-10576288
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105762882023-10-15 Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis Papp, Márton Kiss, Nikolett Baka, Máté Trásy, Domonkos Zubek, László Fehérvári, Péter Harnos, Andrea Turan, Caner Hegyi, Péter Molnár, Zsolt Crit Care Research BACKGROUND: Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guided AB therapy with standard of care (SOC) in critically ill patients. METHODS: We searched databases CENTRAL, Embase and Medline. We included randomized controlled trials (RCTs) comparing PCT-guided AB therapy (PCT group) with SOC reporting on length of AB therapy, mortality, recurrent and secondary infection, ICU length of stay (LOS), hospital LOS or healthcare costs. Due to recent changes in sepsis definitions, subgroup analyses were performed in studies applying the Sepsis-3 definition. In the statistical analysis, a random-effects model was used to pool effect sizes. RESULTS: We included 26 RCTs (n = 9048 patients) in the quantitative analysis. In comparison with SOC, length of AB therapy was significantly shorter in the PCT group (MD − 1.79 days, 95% CI: -2.65, − 0.92) and was associated with a significantly lower 28-day mortality (OR 0.84, 95% CI: 0.74, 0.95). In Sepsis-3 patients, mortality benefit was more pronounced (OR 0.46 95% CI: 0.27, 0.79). Odds of recurrent infection were significantly higher in the PCT group (OR 1.36, 95% CI: 1.10, 1.68), but there was no significant difference in the odds of secondary infection (OR 0.81, 95% CI: 0.54, 1.21), ICU and hospital length of stay (MD − 0.67 days 95% CI: − 1.76, 0.41 and MD − 1.23 days, 95% CI: − 3.13, 0.67, respectively). CONCLUSIONS: PCT-guided AB therapy may be associated with reduced AB use, lower 28-day mortality but higher infection recurrence, with similar ICU and hospital length of stay. Our results render the need for better designed studies investigating the role of PCT-guided AB stewardship in critically ill patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04677-2. BioMed Central 2023-10-13 /pmc/articles/PMC10576288/ /pubmed/37833778 http://dx.doi.org/10.1186/s13054-023-04677-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Papp, Márton
Kiss, Nikolett
Baka, Máté
Trásy, Domonkos
Zubek, László
Fehérvári, Péter
Harnos, Andrea
Turan, Caner
Hegyi, Péter
Molnár, Zsolt
Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
title Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
title_full Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
title_fullStr Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
title_full_unstemmed Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
title_short Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
title_sort procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576288/
https://www.ncbi.nlm.nih.gov/pubmed/37833778
http://dx.doi.org/10.1186/s13054-023-04677-2
work_keys_str_mv AT pappmarton procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT kissnikolett procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT bakamate procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT trasydomonkos procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT zubeklaszlo procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT fehervaripeter procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT harnosandrea procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT turancaner procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT hegyipeter procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis
AT molnarzsolt procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis